<DOC>
	<DOCNO>NCT02335424</DOCNO>
	<brief_summary>This study use pembrolizumab ( MK-3475 , KEYTRUDAÂ® ) first-line treatment participant advanced/unresectable ( inoperable ) metastatic urothelial cancer ineligible cisplatin-based therapy . The primary study objective determine objective response rate ( ORR ) participant , participant whose tumor rely program cell death ligand 1 ( PD-L1 ) protein ( PD-L1-positive tumor ) , participant strongly PD-L1-positive tumor .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Participants With Advanced Urothelial Cancer ( MK-3475-052/KEYNOTE-52 )</brief_title>
	<detailed_description>Participants receive pembrolizumab attain complete response ( CR ) may consider stop trial treatment meet criterion hold therapy . Participants stop trial treatment receive 24 month trial treatment reason progressive disease ( PD ) intolerability , participant attain CR stop trial treatment may eligible one year retreatment upon experience PD .</detailed_description>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologically cytologicallyconfirmed diagnosis advanced/unresectable ( inoperable ) metastatic urothelial cancer renal pelvis , ureter , bladder , urethra ( transitional cell mixed transitional/nontransitional cell histology ) Ineligible cisplatin therapy No prior systemic chemotherapy metastatic disease ( adjuvant neoadjuvant platinumbased chemotherapy recurrence &gt; 12 month since completion therapy allow ) Available tissue newly obtain core excisional biopsy tumor lesion previously irradiate Measureable disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Adequate organ function Female participant childbearing potential negative urine serum pregnancy test ; surgically sterile , willing use 2 acceptable method birth control , abstain heterosexual activity course study 120 day last dose study treatment Male participant must willing use adequate method contraception start first dose study medication 120 day last dose study treatment Disease suitable local therapy administer curative intent Currently participate participate study investigational agent receive study therapy use investigational device within 4 week prior first dose study treatment Prior anticancer monoclonal antibody ( mAb ) direct antineoplastic treatment within 4 week prior study Day 1 recover adverse event due agent administer 4 week earlier Prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover AEs due previously administer agent Known additional malignancy progress require active treatment except basal cell carcinoma skin , squamous cell carcinoma skin undergone potentially curative therapy , situ cancer Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Active autoimmune disease require systemic treatment past 2 year Evidence interstitial lung disease active noninfectious pneumonitis Active infection require systemic therapy Pregnant breastfeeding , expect conceive father child within project duration trial , start screen visit 120 day last dose study treatment Prior therapy antiPD1 , antiPDL1 , antiPDL2 agent , agent direct another coinhibitory Tcell receptor Known human immunodeficiency virus ( HIV ) Known active Hepatitis B C Received live virus vaccine within 30 day plan start study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>P-D1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PD1</keyword>
	<keyword>P-DL1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PDL-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>Bladder cancer</keyword>
</DOC>